Ernexa Therapeutics (ERNAW) Receivables - Other (2018 - 2026)
Ernexa Therapeutics (ERNAW) reported Receivables - Other of $95000.0 for Q1 2026, down 39.1% on a YoY basis from $156000.0 in Q1 2025, and down 87.33% quarter-over-quarter from $750000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Receivables - Other (2018 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Receivables - Other for 9 years, with the latest figure at $95000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other fell 39.1% year-over-year to $95000.0; the trailing twelve-month figure through Mar 2026 stood at $95000.0 (down 39.1% YoY), and the FY2021 full-year result was $684000.0, up 510.71% from the prior year.
- Receivables - Other for Q1 2026 stood at $95000.0, down from $750000.0 in the prior quarter.
- The five-year high for Receivables - Other was $1.8 million in Q3 2023, with the low at $95000.0 in Q1 2026.
- Historically, Receivables - Other has averaged $566857.1 across 5 years, with a median of $499000.0 in 2023.
- Annual changes were most pronounced in 2023 — Receivables - Other surged 91.79% — and 2024, when it tumbled 89.47%.
- Ernexa Therapeutics' Receivables - Other stood at $926000.0 in 2022, then surged by 91.79% to $1.8 million in 2023, then plunged by 89.47% to $187000.0 in 2024, then soared by 301.07% to $750000.0 in 2025, then slumped by 87.33% to $95000.0 in 2026.
- The last three Receivables - Other figures came in at $95000.0 (Q1 2026), $750000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95,000.00 |
| Mar 31, 2026 | 95,000.00 |
| Dec 31, 2025 | 750,000.00 |
| Dec 31, 2025 | 750,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 351,000.00 |
| Mar 31, 2024 | 351,000.00 |
| Sep 30, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 984,000.00 |
| Jun 30, 2023 | 984,000.00 |